Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

NIAID Data Ecosystem2026-03-10 收录

转移性结直肠癌维持与支持治疗

阿帕替尼-卡培他滨联合用药

数据链接：

https://www.omicsdi.org/dataset/ecrin-mdr-crc/2242757 数据链接链接失效反馈

官方服务：

资源简介：

To control apatinib and capecitabine combination to maintain treating metastatic colorectal cancer.

创建时间：

2017-04-15

Maintenance Treatment With Capecitabine Metronomic Chemotherapy and Chinese Traditional Medicine in Metastatic Colorectal Cancer

转移性结直肠癌维持与支持治疗

中西医结合治疗

The optimum regimen of maintenance treatment after first-line chemotherapy in patients with metastatic colorectal cancer （mCRC） is unknown. This study was designed to determine the efficacy and safety

NIAID Data Ecosystem90

Xeloda Maintenance Versus BSC in Metastatic Colorectal Cancer

转移性结直肠癌维持与支持治疗

化疗疗效评估

Colorectal cancer (CRC) accounts for 10% to 15% of all cancers and is the second leading cause of cancer deaths in Western countries. Approximately half of all patients develop metastatic disease and

NIAID Data Ecosystem50

Optimized Chemotherapy Followed by Maintenance With Bevacizumab With or Without Erlotinib in Treating Patients With Metastatic Colorectal Cancer That Cannot be Removed by Surgery (DREAM)

转移性结直肠癌维持与支持治疗

抗肿瘤药物疗效评估

PURPOSE: This randomized phase III trial is studying maintenance therapy with bevacizumab alone after an induction therapy combining bevacizumab+chemotherapy to see how well they work compared to main

NIAID Data Ecosystem40

Maintenance Tislelizumab + Capecitabine to Treat Metastatic Colorectal Cancer

转移性结直肠癌维持与支持治疗

化疗疗效评估

Surgery with integrated treatment for metastatic colorectal cancer (mCRC) has created a new clinical setting known as mCRC with no evidence of disease (NED). However, these patients have a high risk o

NIAID Data Ecosystem60

Biological-guided Metronomic Chemotherapy as Maintenance Strategy in Metastatic Colorectal Cancer

转移性结直肠癌维持与支持治疗

肿瘤生物标志物

Based upon biological behavior, those mCRC patients who respond well (SD, PR or CR according to RECIST Criteria) after 16-18 weeks of standard doublet chemotherapy as induction may enrolled into this

NIAID Data Ecosystem40

Study of Apatinib and Capecitabine Combination to Maintain Treating Metastatic Colorectal Cancer

资源简介：

相关数据集